Cellosaurus Kasumi-1 (CVCL_0589)

Cell line name Kasumi-1
Synonyms KASUMI-1; Kasumi 1; KASUMI1; Kasumi1
Accession CVCL_0589
Resource Identification Initiative To cite this cell line use: Kasumi-1 (RRID:CVCL_0589)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: MD Anderson Cell Lines Project.
Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
Doubling time: 40-45 hours (PubMed=2018839); 40 hours (PubMed=25984343); 53 hours (PubMed=20922763); ~48-72 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Sequence variation: RAD21 p.Lys330Profs*6 (PubMed=23955599).
Omics: Array-based CGH.
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Misspelling: Kusami-1; In Cosmic 1516633 and Cosmic 1623636.
Misspelling: KUSAMI-1; In Cosmic 2306211.
Derived from sampling site: Peripheral blood.
Disease Childhood acute myeloid leukemia with maturation (NCIt: C9381)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_JY44 (Kasumi-1 R48)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): ATCC; CLS; Cosmic-CLP; COG; DSMZ; JCRB; PubMed=20922763; PubMed=25877200

Markers:
AmelogeninX
CSF1PO10,12
D13S31711,13
D16S5399,12
D18S5115,16
D19S43313,15.2
D21S1130,31
D2S133819
D3S135815,17
D5S8189,11
D7S8208,11
D8S117913,14
FGA22,24
Penta D12
Penta E11
TH016,9
TPOX8,9
vWA14 (ATCC; CLS; Cosmic-CLP; DSMZ; JCRB; PubMed=20922763; PubMed=25877200)
14,18 (COG)
Web pages http://www.cogcell.org/cellreqs-ncipptp.php
http://www.pptpinvitro.org/cell_lines_panel.php
http://tcpaportal.org/mclp/
Publications

PubMed=2018839
Asou H., Tashiro S., Hamamoto K., Otsuji A., Kita K., Kamada N.
Establishment of a human acute myeloid leukemia cell line (Kasumi-1) with 8;21 chromosome translocation.
Blood 77:2031-2036(1991)

PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x
Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T., Aizawa Y., Ueda R., Seto M.
Expression of the TCL1 gene at 14q32 in B-cell malignancies but not in adult T-cell leukemia.
Jpn. J. Cancer Res. 89:712-718(1998)

PubMed=15621809; DOI=10.1080/10428190400007565
Larizza L., Magnani I., Beghini A.
The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia.
Leuk. Lymphoma 46:247-255(2005)

PubMed=15843827; DOI=10.1038/sj.leu.2403749
Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J., Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M., Fioretos T.
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.
Leukemia 19:1042-1050(2005)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=16523483; DOI=10.1002/gcc.20317
Horsley S.W., Mackay A., Iravani M., Fenwick K., Valgeirsson H., Dexter T., Ashworth A., Kearney L.
Array CGH of fusion gene-positive leukemia-derived cell lines reveals cryptic regions of genomic gain and loss.
Genes Chromosomes Cancer 45:554-564(2006)

PubMed=18385756; DOI=10.1038/leu.2008.61
Becker H., Pfeifer D., Afonso J.D., Nimer S.D., Veelken H., Schwabe M., Lubbert M.
Two cell lines of t(8;21) acute myeloid leukemia with activating KIT exon 17 mutation: models for the 'second hit' hypothesis.
Leukemia 22:1792-1794(2008)

PubMed=20922763; DOI=10.1002/pbc.22801
Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J., Reynolds C.P.
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.
Pediatr. Blood Cancer 56:239-249(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23955599; DOI=10.1038/ng.2731
Kon A., Shih L.-Y., Minamino M., Sanada M., Shiraishi Y., Nagata Y., Yoshida K., Okuno Y., Bando M., Nakato R., Ishikawa S., Sato-Otsubo A., Nagae G., Nishimoto A., Haferlach C., Nowak D., Sato Y., Alpermann T., Nagasaki M., Shimamura T., Tanaka H., Chiba K., Yamamoto R., Yamaguchi T., Otsu M., Obara N., Sakata-Yanagimoto M., Nakamaki T., Ishiyama K., Nolte F., Hofmann W.K., Miyawaki S., Chiba S., Mori H., Nakauchi H., Koeffler H.P., Aburatani H., Haferlach T., Shirahige K., Miyano S., Ogawa S.
Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms.
Nat. Genet. 45:1232-1237(2013)

PubMed=24211243; DOI=10.1016/j.exphem.2013.10.006
Herrmann M.D., Lennerz J.K., Bullinger L., Bartholomae S., Holzmann K., Westhoff M.-A., Corbacioglu S., Debatin K.-M.
Transitory dasatinib-resistant states in KIT(mut) t(8;21) acute myeloid leukemia cells correlate with altered KIT expression.
Exp. Hematol. 42:90-100(2014)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections ATCC; CRL-2724
BCRC; 60505
BCRJ; 0305
CLS; 300226/p633_Kasumi-1
DSMZ; ACC-220
IZSLER; BS TCL 242
JCRB; JCRB1003
JCRB; NIHS0235 - Discontinued
Cell line databases/resources CLDB; cl2998
CCLE; KASUMI1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
Cosmic-CLP; 907275
GDSC; 907275
LINCS_LDP; LCL-1055
Ontologies BTO; BTO:0004136
CLO; CLO_0007068
CLO; CLO_0007069
EFO; EFO_0006607
MCCL; MCC:0000264
Biological sample resources BioSample; SAMN01821572
BioSample; SAMN01821642
BioSample; SAMN01821688
BioSample; SAMN03473161
Chemistry resources ChEMBL-Cells; CHEMBL3307835
ChEMBL-Targets; CHEMBL613988
Gene expression databases GEO; GSM236785
GEO; GSM236821
GEO; GSM482490
GEO; GSM506744
GEO; GSM506867
GEO; GSM506973
GEO; GSM887197
GEO; GSM888270
GEO; GSM955189
GEO; GSM955190
GEO; GSM955191
GEO; GSM1374590
GEO; GSM1446745
GEO; GSM1669979
Other Wikidata; Q38098914
Polymorphism and mutation databases Cosmic; 787441
Cosmic; 907275
Cosmic; 975258
Cosmic; 981579
Cosmic; 987968
Cosmic; 1012076
Cosmic; 1078725
Cosmic; 1149336
Cosmic; 1181600
Cosmic; 1451847
Cosmic; 1476423
Cosmic; 1509202
Cosmic; 1516633
Cosmic; 1524831
Cosmic; 1623636
Cosmic; 1779131
Cosmic; 2089650
Cosmic; 2131540
Cosmic; 2306211
Proteomic databases PRIDE; PXD000185